Seeking Alpha

Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M...

Endocyte (ECYT) +110.5% premarket after Merck (MRK) agrees to pay the biotech company $120M upfront plus milestone payouts of up to $880M to develop and market experimental cancer drug vintafolide, which is being evaluated in a Phase 3 clinical trial for ovarian cancer and a Phase 2 trial for non-small cell lung cancer. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|